NCT03030625View on ClinicalTrials.gov

VMAT for Dominant Intraprostatic Lesion

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 13, 2017

Primary Completion Date

January 25, 2023

Study Completion Date

January 25, 2023

Conditions
Prostate Cancer
Interventions
RADIATION

IGRT/VMAT focal therapy boost to DIL

Image-guided/VMAT focal Intensification dose to intraprostatic dominant lesion in men with localized prostate cancer (PCa) of intermediate and high risk (criteria NCCN) eligible to receive radiotherapy

Trial Locations (1)

28006

Hospital Universitario de la Princesa, Madrid

All Listed Sponsors
lead

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

OTHER

NCT03030625 - VMAT for Dominant Intraprostatic Lesion | Biotech Hunter | Biotech Hunter